Aurobindo Pharma Limited news

Aurobindo Pharma Limited is pleased to announce that its joint venture company, Eugia Pharma Specialities Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Methotrexate tablets, 2.5 mg. Methotrexate tablets are generic version of Dava Pharmaceuticals’ Rheumatrex Tablets. The product will be launched in March 2020. The approved product has an estimated market size of US$ 98 million for the twelve months ending December 201

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC). Aurobindo’s Guaifenesin extended-release tablets are the AB rated generic equivalent of RB Health (US) LLC’s Mucinex® tablets. The product is expected to launch in Q4FY20. Guaifenesin extended-release tablets helps to loosen phlegm (mucus), and thin bronchia

Hyderabad, India, 17th January 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US. Acrotech Biopharma LLC (“Acrotech”), a wholly-owned subsidiary of Aurobindo Pharma USA Inc., which in turn a wholly-owned subsidiar

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Potassium Chloride ExtendedRelease tablets, 8 mEq (600 mg) and 10 mEq (750 mg). Potassium Chloride Extended-Release tablets, a generic version of Upsher-Smith’s Klor-Con® Extended Release tablets. The product will be launched in January 2019. Potassium Chloride tablets are indicated for the treatment of hypokalemia,

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin Oral Suspension 100 mg /5 mL and 200 mg/5 mL. Azithromycin oral suspension, a generic version of Pfizer Inc’s Zithromax® oral suspension. The product will be launched in November 2018. Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections. The approved